# US 2023/0068087 A1 · Gene therapy for neurodegenerative disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068087 A1
- Document ID: US20230068087A1
- Status: Published application
- Kind: A1
- Application number: 17/779,980
- Filed: 2020-11-25
- Published: 2023-03-02
- Earliest claimed: 2019-11-29
- Assignees: Paros Bio, Inc.
- Applicants: Paros Bio, Inc.
- Inventors: Kimberley S. Gannon; Martin Goulet; Neil R. Hackett
- Web page: https://patentgrep.com/patent/US20230068087A1

## CPC

- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N 2840/10: regulates levels of translation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure relates to nucleic acid expression cassettes for the treatment of neurodegenerative disorders. Methods of treating neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, cognitive impairment, and mild cognitive impairment are also provided.

## Claims

### Claim 1

An isolated polynucleotide set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39; or having at least 95% sequence identity to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39, and encoding the same polypeptide encoded by each of the foregoing, wherein the polynucleotide is not naturally occurring.

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1, having the nucleotide sequence set forth in SEQ ID NO:37.

### Claim 3 (depends on 1)

The isolated polynucleotide of claim 1, having the nucleotide sequence set forth in SEQ ID NO:39.

### Claim 4

A nucleic acid expression cassette comprising:
(I) a polynucleotide encoding presenilin 1, wherein the polynucleotide comprises any one of:
(a) a polynucleotide set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39; or
(b) a polynucleotide having at least 95% identity to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39; and
(II) one or more regulatory elements operably linked to the polynucleotide encoding presenilin 1.

### Claim 5 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein one of the regulatory elements is a Kozak translation initiation signal.

### Claim 6 (depends on 5)

The nucleic acid expression cassette of claim 5, wherein the Kozak translation initiation signal comprises a polynucleotide set forth in SEQ ID NO:5.

### Claim 7 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein one of the regulatory elements is a chromatin insulator sequence.

### Claim 8 (depends on 7)

The nucleic acid expression cassette of claim 7, wherein the chromatin insulator sequence comprises a polynucleotide set forth in SEQ ID NO:4.

### Claim 9 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein one of the regulatory elements is a neuron-specific promoter.

### Claim 10 (depends on 9)

The nucleic acid expression cassette of claim 9, wherein the neuron-specific promoter comprises (i) a polynucleotide set forth in SEQ ID NO:2; (ii) a polynucleotide set forth in SEQ ID NO:3; (iii) a functional fragment of SEQ ID NO:2 or SEQ ID NO:3; or (iv) a polynucleotide with at least 95% identity to (i), (ii), or (iii).

### Claim 11 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein one or more of the regulatory elements is independently selected from a mRNA stability element.

### Claim 12 (depends on 11)

The nucleic acid expression cassette of claim 11, wherein the mRNA stability element comprises (i) a polynucleotide set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11; (ii) a polynucleotide with at least 95% sequence identity to SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11.

### Claim 13 (depends on 11)

The nucleic acid expression cassette of claim 11, wherein the mRNA stability element is located 3′ of an open reading frame of the polynucleotide encoding presenilin 1 or 5′ of a polyadenylation signal.

### Claim 14 (depends on 13)

The nucleic acid expression cassette of claim 13 comprising a first and a second mRNA stability element, wherein the first mRNA stability element is located 3′ of an open reading frame of the polynucleotide encoding presenilin 1; and the second mRNA stability element is located 5′ of a polyadenylation signal.

### Claim 15 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein the polynucleotide encoding presenilin 1 is the polynucleotide set forth in SEQ ID NO:37.

### Claim 16 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein the polynucleotide encoding presenilin 1 is the polynucleotide set forth in SEQ ID NO:39.

### Claim 17 (depends on 4)

A vector comprising the nucleic acid expression cassette of claim 4.

### Claim 18 (depends on 17)

The vector of claim 17, wherein the vector is a viral vector.

### Claim 19 (depends on 18)

The vector of claim 18, wherein the viral vector is an adeno-associated virus (AAV) vector, a retroviral vector, a lentiviral vector, or an adenoviral vector.

### Claim 20 (depends on 19)

The vector of claim 19, wherein the AAV vector is AAV1, AAV2, AAV3, AAV4, AAVS, AAV6, AAV7, AAV8, AAV9, AAVDJ, AAVrh10, AAV11, AAV12, AAV2/1, AAV2/5, AAV2/6, AAV2/7, AAV2/8, AAV2/9, AAV2/rh10, AAV2/11, or AAV2/12.

### Claim 21 (depends on 19)

The vector of claim 19, wherein the vector comprises:
a. a promoter selected from a CAG promoter, a presenilin-1 promoter, a ubiquitin C promoter, a CBA promoter, a synapsin-1 promoter, a PGK promoter, and an EF1α promoter, operatively linked to:
b. a presenilin-1 coding sequence selected from SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39, or a polynucleotide having at least 95% identity to any of the foregoing PSEN-1 coding sequences and encoding a wild-type PSEN-1 amino acids sequence; and
c. a polyadenylation sequence selected from a human growth hormone polyadenylation sequence and a rabbit β-globin polyadenylation sequence.

### Claim 22 (depends on 21)

The vector of claim 21 additionally comprising an intron selected from a human beta globin intron (either wild-type or synthetic) or a minute virus of mice intron, wherein the intron is located in between the promoter and the PSEN-1 coding sequence.

### Claim 23 (depends on 22)

The vector of claim 22, wherein the vector comprises:
a. nucleotides 1-141 of SEQ ID NO:41 or a sequence having at least 95% identity thereto, nucleotides 237-1200 of SEQ ID NO:41 or a sequence having at least 95% identity thereto, nucleotides 1221-1786 of SEQ ID NO:41 or a sequence having at least 95% identity thereto, nucleotides 1899-3299 of SEQ ID NO:41 or a sequence having at least 95% identity thereto, nucleotides 3330-3806 of SEQ ID NO:41 or a sequence having at least 95% identity thereto and nucleotides 4553-4693 of SEQ ID NO:41 or a sequence having at least 95% identity thereto;
b. Nucleotides 1-141 of SEQ ID NO:42 or a sequence having at least 95% identity thereto, nucleotides 237-1323 of SEQ ID NO:42 or a sequence having at least 95% identity thereto, nucleotides 1344-1909 of SEQ ID NO:42 or a sequence having at least 95% identity thereto, nucleotides 1983-3416 of SEQ ID NO:42 or a sequence having at least 95% identity thereto, nucleotides 3447-3923 of SEQ ID NO:42 or a sequence having at least 95% identity thereto, and nucleotides 4554-4694 of SEQ ID NO:42 or a sequence having at least 95% identity thereto;
c. Nucleotides 1-141 of SEQ ID NO:43 or a sequence having at least 95% identity thereto, nucleotides 237-890 of SEQ ID NO:43 or a sequence having at least 95% identity thereto, nucleotides 911-1476 of SEQ ID NO:43 or a sequence having at least 95% identity thereto, nucleotides 1550-2983 of SEQ ID NO:43 or a sequence having at least 95% identity thereto, nucleotides 3014-3490 of SEQ ID NO:43 or a sequence having at least 95% identity thereto, and nucleotides 4553-4694 or a sequence having at least 95% identity thereto of SEQ ID NO:43;
d. Nucleotides 1-141 or a sequence having at least 95% identity thereto, nucleotides 237-1415 or a sequence having at least 95% identity thereto, nucleotides 1436-2001 or a sequence having at least 95% identity thereto, nucleotides 2075-3508 or a sequence having at least 95% identity thereto, nucleotides 3539-4015 or a sequence having at least 95% identity thereto, and nucleotides 4500-4640 or a sequence having at least 95% identity thereto of SEQ ID NO:44 or a sequence having at least 95% identity thereto;
e. Nucleotides 1-141 of SEQ ID NO:45 or a sequence having at least 95% identity thereto, nucleotides 237-664 of SEQ ID NO:45 or a sequence having at least 95% identity thereto, nucleotides 684-1249 of SEQ ID NO:45 or a sequence having at least 95% identity thereto, nucleotides 1323-2756 of SEQ ID NO:45 or a sequence having at least 95% identity thereto, 2787-3263 of SEQ ID NO:45 or a sequence having at least 95% identity thereto, and nucleotides 4533-4673 of SEQ ID NO:45 or a sequence having at least 95% identity thereto;
f. Nucleotides 1-141 of SEQ ID NO:46 or a sequence having at least 95% identity thereto, nucleotides 237-684 of SEQ ID NO:46 or a sequence having at least 95% identity thereto, nucleotides 705-1270 of SEQ ID NO:46 or a sequence having at least 95% identity thereto, nucleotides 1344-2777 of SEQ ID NO:46 or a sequence having at least 95% identity thereto, nucleotides 2808-3284 of SEQ ID NO:46 or a sequence having at least 95% identity thereto, and nucleotides 4554-4695 of SEQ ID NO:46 or a sequence having at least 95% identity thereto; or
g. Nucleotides 1-105 of SEQ ID NO:47 or a sequence having at least 95% identity thereto, nucleotides 113-766 of SEQ ID NO:47 or a sequence having at least 95% identity thereto, nucleotides 776-867 of SEQ ID NO:47 or a sequence having at least 95% identity thereto, nucleotides 881-2311 of SEQ ID NO:47 or a sequence having at least 95% identity thereto, nucleotides 2319-2367 of SEQ ID NO:47 or a sequence having at least 95% identity thereto, and nucleotides 2386-2526 of SEQ ID NO:47 or a sequence having at least 95% identity thereto.

### Claim 24 (depends on 23)

The vector of claim 23, wherein the vector comprises a nucleotide sequence of any one of SEQ ID NOs:41-47 or a nucleotide sequence having 95% identity to any one of SEQ ID NOs:41-47.

### Claim 25 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein the regulatory elements operably linked to the polynucleotide encoding presenilin 1 comprise:
(i) a Kozak translation initiation signal;
(ii) a neuron-specific promoter;
(iii) a chromatin insulator sequence;
(iv) a mRNA stability element located 3′ of an open reading frame of the polynucleotide encoding presenilin 1; and
(v) a mRNA stability element located 5′ of a polyadenylation signal.

### Claim 26 (depends on 25)

The nucleic acid expression cassette of claim 25, wherein:
the Kozak translation initiation signal comprises a polynucleotide set forth in SEQ ID NO:5;
the chromatin insulator sequence comprises a polynucleotide set forth in SEQ ID NO:4;
the mRNA stability element located 3′ of the open reading frame of the polynucleotide encoding presenilin 1 comprises a polynucleotide set forth in SEQ ID NO:9, or SEQ ID NO:10;
the at least one mRNA stability element located 5′ of a polyadenylation signal comprises a polynucleotide set forth in SEQ ID NO:11; and
the neuron-specific promoter comprises a polynucleotide set forth in SEQ ID NO:2 or SEQ ID NO:3.

### Claim 27 (depends on 4)

The nucleic acid expression cassette of claim 4, wherein the promoter operably linked to the polynucleotide encoding presenilin 1 is a ubiquitous promoter.

### Claim 28 (depends on 17)

A method of treating a neurodegenerative disease, disorder, or condition comprising administering to a subject in need thereof the vector of claim 17.

### Claim 29 (depends on 28)

The method of claim 28, wherein the neurodegenerative disease, disorder, or condition is Alzheimer's disease, Familial Alzheimer's Disease (FAD), presenilin 1 (PSEN-1) mediated FAD, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, cognitive impairment, or mild cognitive impairment.

### Claim 30 (depends on 17)

A method of treating Familial Alzheimer's Disease (FAD) or presenilin 1 (PSEN-1) mediated FAD comprising administering to a subject in need thereof the vector of claim 17.

### Claim 31

A method of producing presenilin 1 protein comprising:
transforming a host cell with a vector comprising an optimized polynucleotide set forth in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39; or by a vector comprising a polynucleotide having at least 95% identity to SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, or SEQ ID NO:39, and encoding the same polypeptide encoded by each of the foregoing; and
culturing the cell under conditions and for a time that allow expression of the presenilin 1 protein, wherein the expression of the presenilin 1 protein encoded by the optimized polynucleotide in the host cell is greater than a level of expression of presenilin 1 protein encoded by a wild-type polynucleotide in a host cell, thereby producing presenilin 1 protein.
